Literature DB >> 16541207

Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis.

C M Gordon1, E Binello, M S LeBoff, M E Wohl, C J Rosen, A A Colin.   

Abstract

INTRODUCTION: Patients with cystic fibrosis (CF) are known to be at risk for early osteoporosis, and the mechanisms that mediate bone loss are still being delineated. The aim of the present investigation was to investigate if a correlation exists in these patients between skeletal measurements by dual-energy x-ray absorptiometry (DXA) and two anabolic factors, dehydroepiandrosterone (DHEA) and insulin-like growth factor I (IGF-I), and proresorptive factors such as the cytokines interleukin-1beta, tumor necrosis factor alpha, and interleukin-6.
METHODS: We studied 32 outpatients (18 females; mean age: 26.2+/-7.9 years) at a tertiary care medical center. The subjects had venous samples obtained, underwent anthropometric and bone mineral density (BMD) measurements, and completed a health survey. Serum IGF-I concentrations were below the age-adjusted mean in 78% of the participants, and DHEA sulfate (DHEAS) concentrations were low in 72%. Serum concentrations of all cytokines were on the low side of normal; nonetheless, there was a modest inverse correlation between IL-1beta and BMD at all sites.
RESULTS: In univariate analyses, IGF-I and DHEAS were significant correlates of BMD or bone mineral content. In final multivariate models controlling for anthropometric and other variables of relevance to bone density, only IGF-I was identified as a significant independent skeletal predictor. While alterations in DHEAS, IGF-I, and specific cytokines may contribute to skeletal deficits in patients with CF, of these factors a low IGF-I concentration appears to be most strongly correlated with BMD.
CONCLUSIONS: These findings may have therapeutic implications for enhancing bone density in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541207      PMCID: PMC3206625          DOI: 10.1007/s00198-005-0058-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  49 in total

1.  Adrenal and gonadal steroids inhibit IL-6 secretion by human marrow cells.

Authors:  C M Gordon; M S LeBoff; J Glowacki
Journal:  Cytokine       Date:  2001-12-07       Impact factor: 3.861

2.  Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial.

Authors:  Catherine M Gordon; Estherann Grace; S Jean Emans; Henry A Feldman; Elizabeth Goodman; Kelly A Becker; Clifford J Rosen; Caren M Gundberg; Meryl S LeBoff
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

3.  Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study.

Authors:  H A Wojtczak; G S Kerby; J S Wagener; S C Copenhaver; R W Gotlin; D W Riches; F J Accurso
Journal:  Pediatr Pulmonol       Date:  2001-10

4.  Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis.

Authors:  R M Aris; A R Stephens; D A Ontjes; A Denene Blackwood; R K Lark; M B Hensler; I P Neuringer; G E Lester
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

5.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

6.  Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study.

Authors:  S L Elkin; A Fairney; S Burnett; M Kemp; P Kyd; J Burgess; J E Compston; M E Hodson
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

Review 7.  Growth problems and growth hormone treatment in children with cystic fibrosis.

Authors:  Dana S Hardin
Journal:  J Pediatr Endocrinol Metab       Date:  2002-05       Impact factor: 1.634

8.  Physiologic regulators of bone turnover in young women with anorexia nervosa.

Authors:  Catherine M Gordon; Elizabeth Goodman; S Jean Emans; Estherann Grace; Kelly A Becker; Clifford J Rosen; Caren M Gundberg; Meryl S Leboff
Journal:  J Pediatr       Date:  2002-07       Impact factor: 4.406

9.  Low serum bone gamma-carboxyglutamic acid protein concentrations in patients with cystic fibrosis: correlation with hormonal parameters and bone mineral density.

Authors:  J De Schepper; J Smitz; I Dab; A Piepsz; M Jonckheer; P Bergmann
Journal:  Horm Res       Date:  1993

10.  Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients.

Authors:  I Sermet-Gaudelus; J C Souberbielle; I Azhar; J C Ruiz; P Magnine; V Colomb; C Le Bihan; D Folio; G Lenoir
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

View more
  12 in total

1.  Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis.

Authors:  Melissa S Putman; Carly E Milliren; Nicholas Derrico; Ahmet Uluer; Leonard Sicilian; Allen Lapey; Gregory Sawicki; Catherine M Gordon; Mary L Bouxsein; Joel S Finkelstein
Journal:  J Clin Endocrinol Metab       Date:  2014-06-13       Impact factor: 5.958

2.  Trajectories of Childhood Blood Pressure and Adult Left Ventricular Hypertrophy: The Bogalusa Heart Study.

Authors:  Tao Zhang; Shengxu Li; Lydia Bazzano; Jiang He; Paul Whelton; Wei Chen
Journal:  Hypertension       Date:  2018-05-21       Impact factor: 10.190

3.  Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period.

Authors:  Melissa S Putman; Joshua F Baker; Ahmet Uluer; Karen Herlyn; Allen Lapey; Leonard Sicilian; Angela Pizzo Tillotson; Catherine M Gordon; Peter A Merkel; Joel S Finkelstein
Journal:  J Cyst Fibros       Date:  2015-02-16       Impact factor: 5.482

Review 4.  Cystic fibrosis-related bone disease: insights into a growing problem.

Authors:  Michael S Stalvey; Gregory A Clines
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-12       Impact factor: 3.243

5.  HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression.

Authors:  Douglas Conrad; Angela Wang; Raymond Pieters; Ferdinando Nicoletti; Katia Mangano; Anna M van Heeckeren; Steven K White; James M Frincke; Christopher L Reading; Dwight Stickney; Dominick L Auci
Journal:  J Inflamm (Lond)       Date:  2010-10-30       Impact factor: 4.981

Review 6.  Chronic pediatric inflammatory diseases: effects on bone.

Authors:  Anuradha Viswanathan; Francisco A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2007-12-29       Impact factor: 6.514

7.  Nutrient status of adults with cystic fibrosis.

Authors:  Catherine M Gordon; Ellen J Anderson; Karen Herlyn; Jane L Hubbard; Angela Pizzo; Rondi Gelbard; Allen Lapey; Peter A Merkel
Journal:  J Am Diet Assoc       Date:  2007-12

8.  Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption.

Authors:  M Matsubara; E Yamachika; H Tsujigiwa; N Mizukawa; T Ueno; J Murakami; N Ishida; Y Kaneda; N Shirasu; S Takagi
Journal:  Osteoporos Int       Date:  2009-10-08       Impact factor: 4.507

9.  Trajectories of childhood BMI and adult diabetes: the Bogalusa Heart Study.

Authors:  Tao Zhang; Jie Xu; Shengxu Li; Lydia A Bazzano; Jiang He; Paul K Whelton; Wei Chen
Journal:  Diabetologia       Date:  2018-10-20       Impact factor: 10.122

Review 10.  Bone Health in Pediatric Patients with IBD: What Is New?

Authors:  Rebecca J Gordon; Catherine M Gordon
Journal:  Curr Osteoporos Rep       Date:  2021-06-22       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.